Business Wire

ADVA

2.6.2020 09:02:12 CEST | Business Wire | Press release

Share
Zenlayer uses ADVA FSP 3000 to tackle huge surge in cloud data demand

ADVA (FSE: ADV) today announced that Zenlayer is deploying its FSP 3000 technology to provide dynamic, highly available services to some of the world’s biggest gaming, cloud computing and social media companies. The solution will deliver flexible, ultra-low-latency connectivity, enabling the cloud service provider to address huge bandwidth needs as and when required. This is essential for Zenlayer’s customers that require highly resilient services with dynamic capacity. Built on the compact and scalable ADVA FSP 3000 platform , the new network will carry multiple services, including Ethernet, Fibre Channel and SONET/SDH. For maximum efficiency and elasticity, it also features ADVA’s QuadFlex™ line cards and OpenFabric™ cross-connect technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005062/en/

“With this deployment, we’re injecting new levels of flexibility and reliability into our infrastructure. ADVA’s technology offers a major boost to our customers who are delivering more and more data-intensive real-time services to their end users. It opens the door to the next generation of teleconferencing, streaming and online gaming technologies,” said Alex Wang, network architect and product manager, Zenlayer. “Our new solution is extremely efficient in terms of footprint and power consumption. It’s also a future-proof investment ready to scale even further in years to come. Another key component in the success of the project was our close working relationship with ADVA’s engineers. They made sure the whole process was seamless and speedy from network design to shipment and implementation.”

Zenlayer’s new transport network includes some of ADVA’s most innovative technology. Specifically designed for scale and bandwidth optimization, the ADVA FSP 3000 platform ensures that the infrastructure meets the most stringent density and energy demands. Using ADVA FSP 3000 QuadFlex™ technology, the solution delivers outstanding spectral efficiency. The new network also features the ADVA FSP 3000 OpenFabric™ , an OTN cross-connect that creates a distributed architecture, empowering Zenlayer to simply and efficiently adjust bandwidth and turn up new services in an instant. What’s more, for Zenlayer customers such as public cloud and global gaming companies, the solution’s low-latency, high-availability performance will translate directly into end-user satisfaction.

“This deployment will benefit a great number of enterprises operating in Taiwan and Singapore. With the ability to flexibly and efficiently transport multi-traffic services at speeds up to 200Gbit/s, Zenlayer’s telecom, cloud service and gaming customers can enhance the experience of their end users and gain a vital competitive edge,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Zenlayer has a clear vision of what its customers expect and a bold strategy for delivering it. By harnessing our technology and the expertise of our engineers, Zenlayer has created a network ready to adapt to evolving demands and able to expand further in years to come.”

“Our open FSP 3000 technology is the ultimate response to ever-increasing data requirements. It gives Zenlayer the tools it needs to grow its network and develop its edge cloud services in a cost-efficient and highly sustainable way,” said Rocky Weicong Zhou, director, global business development, ADVA. “Combined with our QuadFlex™ and OpenFabric™ technologies, our FSP 3000 platform provides superb levels of capacity and agility. It enables Zenlayer to respond flexibly to huge increases in traffic volume while at the same time making savings on energy use and rack space. With a highly flexible and efficient transport system, Zenlayer can give its enterprise customers world-class connectivity to markets across the globe.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye